A SHORT HISTORY
OUR WORK
Human Autocell started as a European coordinated venture in 2003 and quickly developed a name for itself as a leading research and development firm involved in the development of cell regeneration techniques. Its first breakthrough came when its cell regeneration team developed a way to successfully use scaffold technology to grow cell cultures in vitro in its labs. This development is based on two decades of research originating from the work of Langer and Vacanti at MIT in the 1980s.
With further injection of capital, the company was able to build and grow the team to develop this into a procedure approved for patient trials in Germany. German health insurance approved payment of these trials under a new drug rule indicating that the health insurance considered this a highly efficient treatment for an untreatable disease that otherwise could only be treated by transplantation, which is not available for most patients.
In a pre-application clarification meeting with the U.S. FDA, a favourable opinion was given that the method could undergo an accelerated FDA approval process reserved for treatments for which no alternatives exist. Today, of the 75 patients who have received the treatment, the majority have seen the disease arrested and are experiencing a highly improved quality of life.
The current owners at Human Autocell are now in the process of expanding this unique and proven technology. This will require development and trial prior to approval for commercialisation, a process that is estimated to take 3 years.
Need help?
Please get in touch to learn more about working together.
For enquiries, please call
+44 1932 481 444
Email: